p16 Not a Prognostic Marker for Hypopharyngeal Squamous Cell Carcinoma | Cancer Biomarkers | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.234.169. Please contact the publisher to request reinstatement.
1.
Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.  Int J Cancer. 2007;121(8):1813-182017546592PubMedGoogle ScholarCrossref
2.
Kumar B, Cordell KG, Lee JS,  et al.  Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.  Int J Radiat Oncol Biol Phys. 2007;69(2):(Suppl)  S109-S11117848274PubMedGoogle ScholarCrossref
3.
Reimers N, Kasper HU, Weissenborn SJ,  et al.  Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer.  Int J Cancer. 2007;120(8):1731-173817236202PubMedGoogle ScholarCrossref
4.
Shoushtari A, Meeneghan M, Sheng K,  et al.  Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status.  Cancer. 2010;116(11):2645-265420225325PubMedGoogle ScholarCrossref
5.
Ang KK, Harris J, Wheeler R,  et al.  Human papillomavirus and survival of patients with oropharyngeal cancer.  N Engl J Med. 2010;363(1):24-3520530316PubMedGoogle ScholarCrossref
6.
Weinberger PM, Yu Z, Haffty BG,  et al.  Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis.  J Clin Oncol. 2006;24(5):736-74716401683PubMedGoogle ScholarCrossref
7.
Shonka DC Jr, Shoushtari AN, Thomas CY,  et al.  Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.  Arch Otolaryngol Head Neck Surg. 2009;135(11):1126-113219917926PubMedGoogle ScholarCrossref
8.
Clayman GL, Stewart MG, Weber RS, el-Naggar AK, Grimm EA. Human papillomavirus in laryngeal and hypopharyngeal carcinomas: relationship to survival.  Arch Otolaryngol Head Neck Surg. 1994;120(7):743-7488018327PubMedGoogle ScholarCrossref
9.
Lefebvre JL, Ang KK.Larynx Preservation Consensus Panel.  Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.  Int J Radiat Oncol Biol Phys. 2009;73(5):1293-130319306746PubMedGoogle ScholarCrossref
10.
Lewis JS Jr, Thorstad WL, Chernock RD,  et al.  p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status.  Am J Surg Pathol. 2010;34(8):1088-109620588174PubMedGoogle ScholarCrossref
11.
Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers.  J Clin Oncol. 2006;24(17):2606-261116763272PubMedGoogle ScholarCrossref
12.
Rodrigo JP, González MV, Lazo PS,  et al.  Genetic alterations in squamous cell carcinomas of the hypopharynx with correlations to clinicopathological features.  Oral Oncol. 2002;38(4):357-36312076699PubMedGoogle ScholarCrossref
13.
Deng Z, Hasegawa M, Matayoshi S,  et al.  Prevalence and clinical features of human papillomavirus in head and neck squamous cell carcinoma in Okinawa, southern Japan.  Eur Arch Otorhinolaryngol. 2011;268(11):1625-163121328000PubMedGoogle ScholarCrossref
14.
Park JM, Jung CK, Choi YJ,  et al.  The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma.  Hum Pathol. 2010;41(3):431-43719954817PubMedGoogle ScholarCrossref
15.
Karsai S, Abel U, Roesch-Ely M,  et al.  Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis.  J Pathol. 2007;211(3):314-32217152048PubMedGoogle ScholarCrossref
16.
Chen SW, Yang SN, Liang JA, Lin FJ, Tsai MH. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy.  Head Neck. 2009;31(6):709-71619260114PubMedGoogle ScholarCrossref
17.
Hall SF, Groome PA, Irish J, O’Sullivan B. Towards further understanding of prognostic factors for head and neck cancer patients: the example of hypopharyngeal cancer.  Laryngoscope. 2009;119(4):696-70219205009PubMedGoogle ScholarCrossref
18.
Smeets SJ, Hesselink AT, Speel EJ,  et al.  A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.  Int J Cancer. 2007;121(11):2465-247217680565PubMedGoogle ScholarCrossref
Original Article
June 2012

p16 Not a Prognostic Marker for Hypopharyngeal Squamous Cell Carcinoma

Author Affiliations

Author Affiliations: Departments of Radiation Oncology (Drs Wilson and Read and Ms Saylor), Pathology (Dr Stelow), and Otolaryngology–Head and Neck Surgery (Drs Jameson, Shonka, Reibel, and Levine), University of Virginia, Charlottesville; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas (Dr Rahimi).

Arch Otolaryngol Head Neck Surg. 2012;138(6):556-561. doi:10.1001/archoto.2012.950
Abstract

Objective To investigate the prognostic significance of p16 in patients with hypopharyngeal squamous cell carcinoma (HPSCC) and to evaluate the relationship between p16 and human papillomavirus (HPV). Unlike in oropharyngeal SCC (OPSCC), the prognostic significance of p16 in HPSCC and its association with HPV is unclear.

Design Retrospective medical chart review.

Setting University tertiary referral center.

Patients A total of 27 patients with HPSCC treated with definitive radiation therapy between 2002 and 2011 whose tissue was available for immunohistochemical analysis.

Interventions Twenty-two patients were treated with chemoradiation, and 5 with radiation alone. All tumor biopsy specimens were analyzed for p16 and, when sufficient tissue was available, for HPV DNA.

Main Outcome Measures Overall survival (OS), locoregional control (LRC), disease-free survival (DFS), and laryngoesophageal dysfunction–free survival (LEDFS) were analyzed according to p16 status.

Results Findings for p16 were positive in 9 tumors and negative in 18 tumors. Median follow-up was 29.3 months. There was no significant difference in OS, LRC, DFS, or LEDFS for patients with p16-positive vs p16-negative tumors. Only 1 of the 19 tumors tested for HPV was found to be HPV positive. When used as a test for HPV, p16 had a positive predictive value of 17%.

Conclusions In contrast to OPSCC, p16 expression in patients with HPSCC had a low positive predictive value for HPV and did not predict improved OS, LRC, DFS, or LEDFS. Thus, for HPSCC, p16 is not a prognostic biomarker. Caution must be taken when extrapolating the prognostic significance of p16 in patients with OPSCC to patients with head and neck SCC of other subsites.

×